The Defense Department is awarding another $5.8 million to PharmAthene [PIP] for continued development of Protexia, the company’s broad spectrum nerve agent prophylaxis. PharmaAthene in Sept. 2006 received a potential $213 million contract from the Army Space and Missile Command for advanced development of Protexia. As a prophylactic Protexia may reduce or eliminate the need for post-exposure therapeutics.